Skip to main content
OpenTrials

Clinical trial condition

Refractory Hodgkin Lymphoma

Explore clinical trials studying Refractory Hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.

34 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Refractory Hodgkin Lymphoma trial results

Recruiting

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

NCT05272384

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +15 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Yale University New Haven, Connecticut, United States
View Trial Details
Recruiting

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

NCT06487624

Conditions
Advanced Solid Tumor, Bone Diseases, Bone Diseases, Developmental, +15 more
Locations
  • Prisma Health-Upstate Greenville, South Carolina, United States
  • The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, China
  • Zhejiang Provincial Cancer Hospital Hangzhou, China
  • Xuzhou Central Hospital Xuzhou, China
View Trial Details
Not Yet Recruiting

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

NCT07021989

Conditions
Classic Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +9 more
Locations
  • University of California Davis Davis, California, United States
  • University of California San Francisco-Fresno Fresno, California, United States
  • University of California Irvine Irvine, California, United States
  • University of California, San Diego La Jolla, California, United States
View Trial Details
Completed

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

NCT01231412

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +58 more
Locations
  • University of Colorado Denver, Colorado, United States
  • Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
  • Emory University/Winship Cancer Institute Atlanta, Georgia, United States
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
View Trial Details
Completed

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

NCT03213665

Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, +91 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 117 locations
View Trial Details

Related conditions